Wang ME, Chen J, Lu Y, Bawcom AR, Wu J, Ou J, Asara JM, Armstrong AJ, Wang Q, Li L, Wang YZ, Huang J, Chen M. RB1-deficient prostate tumor growth and metastasis are vulnerable to ferroptosis induction via the E2F/ACSL4 axis. Journal of Clinical Investigation. 2023 Mar 16; e166647. doi: 10.1172/JCI166647.

Butler W, Xu L, Zhou Y, Cheng Q, Hauck S, He Y, Marek R, Hartman Z, Cheng L, Yang Q, Wang ME, Chen M, Zhang H, Armstrong AJ, Huang J. Oncofetal protein glypican-3 is a biomarker and critical regulator of function for neuroendocrine cells in prostate cancer. J Pathology. 2023 Feb 8. doi: 10.1002/path.6063.


Chen M*, Huang J*. The expanded role of fatty acid metabolism in cancer: new aspects and targets. Precision Clinical Medicine. 2019 Sep;2(3): 183-191. *Corresponding authors.

Nath D, Li X, Mondragon C, Post D, Chen M, White JR, Hryniewicz-Jankowska A, Caza T, Kuznetsov VA, Hehnly H, Jamaspishvili T, Berman DM, Zhang F, Kung SHY, Fazli L, Gleave ME, Bratslavsky G, Pandolfi PP, Kotula L. Abi1 loss drives prostate tumorigenesis through activation of EMT and non-canonical WNT signaling. Cell Communication and Signaling. 2019 Sep 18;17(1)120.

Han T*, Jiang S*, Zheng H, Yin Q, Xie M, Little MR, Yin X, Chen M, Song SJ, Beg AA, Pandolfi PP, Wan L. Interplay between c-Src and the APC/C co-activator Cdh1 regulates mammary tumorigenesis. Nature Communications. 2019 Aug 16;10(1)3716. *equal contribution.

Lee YR, Chen M, Lee JD*, Zhang J*, Lin SY*, Fu TM, Chen H, Ishikawa T, Chiang SY, Katon J, Zhang Y, Shulga YV, Bester AC, Fung J, Monteleone E, Wan L, Shen C, Hsu CH, Papa A, Clohessy JG, Teruya-Feldsein J, Jain S, Wu H, Matesic L, Chen RH, Wei W, Pandolfi PP. Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway. Science. 2019. May 17;364(6441). *equal contribution.

Chen M, Zhang J, Berger AH, Diolombi MS, Ng C, Fung J, Bronson RT, Castillo-Martin M, Thin TH, Cordon-Cardo C, Plevin R, and Pandolfi PP. Compound haploinsufficiency of Dok2 and Dusp4 promotes lung tumorigenesis. The Journal of Clinical Investigation. 2019. 129(1): 215-222.

Zhang J*, Chen M*, Zhu Y*, Dai X, Dang F, Ren J, Ren S, Shulga YV, Beca F, Gan W, Wu F, Lin Y-M, Zhou X, DeCaprio JA, Beck AH, Lu KP, Huang J, Zhao C, Sun Y, Gao X, Pandolfi PP, and Wei W. SPOP Promotes Nanog Destruction to Suppress Stem Cell Traits and Prostate Cancer Progression. Developmental Cell. 2019. 48(3): 329-344.e5. *equal contribution.

Mugoni V, Panella R*, Cheloni G*, Chen M*, Pozdnyakova O, Stroopinsky D, Guarnerio J, Monteleone E, Lee JD, Mendez L, Menon AV, Aster JC, Lane AA, Stone RM, Galinsky I, Zamora JC, Lo-Coco F, Bhasin MK, Avigan D, Longo L, Clohessy JG, and Pandolfi PP. Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy. Cell Research2019. 29(6): 446-459. *equal contribution.


Chen M, Zhang J, Sampieri K, Clohessy JG, Mendez L, Gonzalez-Billalabeitia E, Liu X-S, Lee Y-R, Fung J, Katon JM, Menon AV, Webster KA, Ng C, Palumbieri MD, Diolombi MS, Breitkopf SB, Teruya-Feldstein J, Signoretti S, Bronson RT, Asara JM, Castillo-Martin M, Cordon-Cardo C, and Pandolfi PP. An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer. Nature Genetics. 2018. 50(2): 206-218.

Chen M, Wan L, Zhang J, Zhang J, Mendez L, Clohessy JG, Berry K, Victor J, Yin Q, Zhu Y, Wei W, and Pandolfi PP. Deregulated PP1α phosphatase activity towards MAPK activation is antagonized by a tumor suppressive failsafe mechanism. Nature Communications. 2018. 9(1): 159.

Lee Y-R*, Chen M*, and Pandolfi PP. The functions and regulation of the PTEN tumour suppressor: new modes and prospects. Nature Reviews. Molecular Cell Biology. 2018. 19(9): 547-562. *equal contribution.

Chen M, and Pandolfi PP. Preclinical and Coclinical Studies in Prostate Cancer. Cold Spring Harbor Perspectives in Medicine. 2018. 8(4). pii: a030544.

Bezzi M, Seitzer N, Ishikawa T, Reschke M, Chen M, Wang G, Mitchell C, Ng C, Katon J, Lunardi A, Signoretti S, Clohessy JG, Zhang J, and Pandolfi PP. Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms. Nature Medicine. 2018. 24(2): 165-175.

Currall BB, Chen M, Sallari RC, Cotter M, Wong KE, Robertson NG, Penney KL, Lunardi A, Reschke M, Hickox AE, Yin Y, Wong GT, Fung J, Brown KK, Williamson RE, Sinnott-Armstrong NA, Kammin T, Ivanov A, Zepeda-Mendoza CJ, Shen J, Quade BJ, Signoretti S, Arnos KS, Banks AS, Patsopoulos N, Liberman MC, Kellis M, Pandolfi PP, and Morton CC. Loss of LDAH associated with prostate cancer and hearing loss. Human Molecular Genetics. 2018. 27(24): 4194-4203.


Wan L*, Chen M*, Cao J*, Dai X*, Yin Q*, Zhang J, Song S-J, Lu Y, Liu J, Inuzuka H, Katon JM, Berry K, Fung J, Ng C, Liu P, Song MS, Xue L, Bronson RT, Kirschner MW, Cui R, Pandolfi PP, and Wei W. The APC/C E3 Ligase Complex Activator FZR1 Restricts BRAF Oncogenic Function. Cancer Discovery. 2017. 7(4): 424-441. *equal contribution.


Shukla-Dave A, Castillo-Martin M, Chen M, Lobo J, Gladoun N, Collazo-Lorduy A, Khan FM, Ponomarev V, Yi Z, Zhang W, Pandolfi PP, Hricak H, and Cordon-Cardo C. Ornithine Decarboxylase Is Sufficient for Prostate Tumorigenesis via Androgen Receptor Signaling. The American Journal of Pathology. 2016. 186(12): 3131-3145.

Chew CL, Chen M, and Pandolfi PP. Endosome and INPP4B. Oncotarget. 2016. 7(1): 5-6.


Li Chew C, Lunardi A, Gulluni F, Ruan DT, Chen M, Salmena L, Nishino M, Papa A, Ng C, Fung J, Clohessy JG, Sasaki J, Sasaki T, Bronson RT, Hirsch E, and Pandolfi PP. In Vivo Role of INPP4B in Tumor and Metastasis Suppression through Regulation of PI3K-AKT Signaling at Endosomes. Cancer Discovery. 2015. 5(7): 740-751.

Lunardi A, Varmeh S, Chen M, Taulli R, Guarnerio J, Ala U, Seitzer N, Ishikawa T, Carver BS, Hobbs RM, Quarantotti V, Ng C, Berger AH, Nardella C, Poliseno L, Montironi R, Castillo-Martin M, Cordon-Cardo C, Signoretti S, and Pandolfi PP. Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis.Cancer Discovery. 2015. 5(5): 550-563.


González-Billalabeitia E, Seitzer N, Song SJ, Song MS, Patnaik A, Liu X-S, Epping MT, Papa A, Hobbs RM, Chen M, Lunardi A, Ng C, Webster KA, Signoretti S, Loda M, Asara JM, Nardella C, Clohessy JG, Cantley LC, and Pandolfi PP. Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition. Cancer Discovery. 2014. 4(8): 896-904.


Papa A, Chen M, and Pandolfi PP. Pills of PTEN? In and out for tumor suppression. Cell Research. 2013. 23(10): 1155-1156.

Berger AH, Chen M, Morotti A, Janas JA, Niki M, Bronson RT, Taylor BS, Ladanyi M, Van Aelst L, Politi K, Varmus HE, and Pandolfi PP. DOK2 inhibits EGFR-mutated lung adenocarcinoma. Plos One. 2013. 8(11): e79526-null.

Vitkus S, Yeh C-R, Lin H-H, Hsu I, Yu J, Chen M, and Yeh S. Distinct function of estrogen receptor α in smooth muscle and fibroblast cells in prostate development. Molecular Endocrinology. 2013. 27(1): 38-49.


Chen M*, Yeh C-R*, Chang H-C, Vitkus S, Wen X-Q, Bhowmick NA, Wolfe A, and Yeh S. Loss of epithelial oestrogen receptor α inhibits oestrogen-stimulated prostate proliferation and squamous metaplasia via in vivo tissue selective knockout models. The Journal of Pathology. 2012. 226(1): 17-27. *equal contribution.

Chen M*, Yeh C-R*, Shyr C-R, Lin H-H, Da J, and Yeh S. Reduced prostate branching morphogenesis in stromal fibroblast, but not in epithelial, estrogen receptor α knockout mice. Asian Journal of Andrology. 2012. 14(4): 546-555. *equal contribution.

Prior to 2012

Nott SL, Huang Y, Kalkanoglu A, Harper K, Chen M, Paoni SF, Fenton BM, and Muyan M. Designer monotransregulators provide a basis for a transcriptional therapy for de novo endocrine-resistant breast cancer. Molecular Medicine2010. 16(1-2): 10-18.

Chen M, Ni J, Chang H-C, Lin C-Y, Muyan M, and Yeh S. CCDC62/ERAP75 functions as a coactivator to enhance estrogen receptor beta-mediated transactivation and target gene expression in prostate cancer cells. Carcinogenesis. 2009. 30(5): 841-850.

Chen M, Hsu I, Wolfe A, Radovick S, Huang K, Yu S, Chang C, Messing EM, and Yeh S. Defects of prostate development and reproductive system in the estrogen receptor-alpha null male mice. Endocrinology. 2009. 150(1): 251-259.

Chen M*, Wolfe A*, Wang X, Chang C, Yeh S, and Radovick S. Generation and characterization of a complete null estrogen receptor alpha mouse using Cre/LoxP technology. Molecular and Cellular Biochemistry. 2009. 321(1-2): 145-153. *equal contribution.

Yin Y, Ni J, Chen M, Guo Y, and Yeh S. RRR-alpha-vitamin E succinate potentiates the antitumor effect of calcitriol in prostate cancer without overt side effects. Clinical Cancer Research. 2009. 15(1): 190-200.

Chen M, Ni J, Zhang Y, Muyan M, and Yeh S. ERAP75 functions as a coactivator to enhance estrogen receptor alpha transactivation in prostate stromal cells. The Prostate. 2008. 68 (12): 1273-1282.

Yin Y, Ni J, Chen M, DiMaggio MA, Guo Y, and Yeh S. The therapeutic and preventive effect of RRR-alpha-vitamin E succinate on prostate cancer via induction of insulin-like growth factor binding protein-3. Clinical Cancer Research. 2007. 13(7): 2271-2280.

Ni J, Wen X, Yao J, Chang H-C, Yin Y, Zhang M, Xie S, Chen M, Simons B, Chang P, di Sant’Agnese A, Messing EM, and Yeh S. Tocopherol-associated protein suppresses prostate cancer cell growth by inhibition of the phosphoinositide 3-kinase pathway. Cancer Research. 2005. 65(21): 9807-9816.

Ni J, Chen M, Zhang Y, Li R, Huang J, and Yeh S. Vitamin E succinate inhibits human prostate cancer cell growth via modulating cell cycle regulatory machinery. Biochemical and Biophysical Research Communications. 2003. 300(2): 357-363.